# Ranjit Akolekar

List of Publications by Year
in descending order



| 198 | 13,612 | 30070 54 | 24258 110 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 209 | 209 | 209 | 9027 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine, 2017, 377, 613-622. | 27.0 | 1,462 |
| 2 | Procedureâ€related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2015, 45, 16-26. | 1.7 | 548 |
| 3 | Analysis of cellâ€free <scp>DNA</scp> in maternal blood in screening for fetal aneuploidies: updated metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2015, 45, 249-266. | 1.7 | 547 |
| 4 | Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. Fetal Diagnosis and Therapy, 2013, 33, 8-15. | 1.4 | 464 |
| 5 | First-Trimester Prediction of Hypertensive Disorders in Pregnancy. Hypertension, 2009, 53, 812-818. | 2.7 | 389 |
| 6 | Prediction of early, intermediate and late preâ€eclampsia from maternal factors, biophysical and biochemical markers at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 66-74. | 2.3 | 377 |
| 7 | Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. American Journal of Obstetrics and Gynecology, 2016, 214, 103.e1-103.e12. | 1.3 | 365 |
| 8 | Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. New England Journal of Medicine, 2016, 374, 434-443. | 27.0 | 308 |
| 9 | Competing risks model in screening for preeclampsia by maternal characteristics and medical history. American Journal of Obstetrics and Gynecology, 2015, 213, 62.e1-62.e10. | 1.3 | 280 |
| 10 | ASPRE trial: performance of screening for preterm preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2017, 50, 492-495. | 1.7 | 263 |
| 11 | Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing. PLoS ONE, 2011, 6, e21791. | 2.5 | 243 |
| 12 | Screening for preâ€eclampsia by maternal factors and biomarkers at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 52, 186-195. | 1.7 | 241 |
| 13 | Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8583-8588. | 7.1 | 233 |
| 14 | Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2008, 32, 732-739. | 1.7 | 222 |
| 15 | Comparison of diagnostic accuracy of early screening for preâ€eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound in Obstetrics and Gynecology, 2018, 51, 743-750. | 1.7 | 219 |
| 16 | Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 442-451. | 1.7 | 217 |
| 17 | Fetal Medicine Foundation fetal and neonatal population weight charts. Ultrasound in Obstetrics and Gynecology, 2018, 52, 44-51. | 1.7 | 197 |
| 18 | Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenatal Diagnosis, 2011, 31, 135-141. | 2.3 | 187 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A Competing Risks Model in Early Screening for Preeclampsia. Fetal Diagnosis and Therapy, 2012, 32, 171-178. | 1.4 | 182 |
| 20 | Accuracy of competingâ€risks model in screening for preâ€eclampsia by maternal factors and biomarkers at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 751-755. | 1.7 | 182 |
| 21 | Combined Screening for Preeclampsia and Small for Gestational Age at 11Â–13 Weeks. Fetal Diagnosis and Therapy, 2013, 33, 16-27. | 1.4 | 180 |
| 22 | Diagnosis of fetal nonâ€chromosomal abnormalities on routine ultrasound examination at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 468-476. | 1.7 | 172 |
| 23 | Prediction of Small-for-Gestation Neonates from Biophysical and Biochemical Markers at 11â€“13 Weeks. Fetal Diagnosis and Therapy, 2011, 29, 148-154. | 1.4 | 153 |
| 24 | Maternal and neonatal complications of fetal macrosomia: systematic review and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 308-318. | 1.7 | 144 |
| 25 | Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology, 2017, 217, 585.e1-585.e5. | 1.3 | 136 |
| 26 | Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-Analysis. Fetal Diagnosis and Therapy, 2014, 35, 156-173. | 1.4 | 132 |
| 27 | Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Ligation for Noninvasive Prenatal Diagnosis of Trisomy 21. Clinical Chemistry, 2010, 56, 459-463. | 3.2 | 125 |
| 28 | Screening for trisomies by cellâ€free DNA testing of maternal blood: consequences of a failed result. Ultrasound in Obstetrics and Gynecology, 2016, 47, 698-704. | 1.7 | 124 |
| 29 | Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. Ultrasound in Obstetrics and Gynecology, 2019, 53, 465-472. | 1.7 | 122 |
| 30 | Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound in Obstetrics and Gynecology, 2017, 50, 228-235. | 1.7 | 112 |
| 31 | Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. Ultrasound in Obstetrics and Gynecology, 2018, 52, 35-43. | 1.7 | 109 |
| 32 | First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical Testing. Fetal Diagnosis and Therapy, 2014, 35, 118-126. | 1.4 | 108 |
| 33 | Clinical implementation of routine screening for fetal trisomies in the <scp>UK</scp><scp>NHS</scp>: cellâ€free <scp>DNA</scp> test contingent on results from firstâ€trimester combined test. Ultrasound in Obstetrics and Gynecology, 2016, 47, 45-52. | 1.7 | 108 |
| 34 | Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2019, 53, 734-742. | 1.7 | 108 |
| 35 | Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 75-83. | 2.3 | 101 |
| 36 | Metabolomics and first-trimester prediction of early-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1840-1847. | 1.5 | 101 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Maternal serum placental protein 13 at 11â€“13 weeks of gestation in preeclampsia. Prenatal Diagnosis, 2009, 29, 1103-1108. | 2.3 | 97 |
| 38 | Prediction and prevention of smallâ€forâ€gestationalâ€age neonates: evidence from SPREE and ASPRE. Ultrasound in Obstetrics and Gynecology, 2018, 52, 52-59. | 1.7 | 91 |
| 39 | Umbilical and fetal middle cerebral artery Doppler at 35â€“37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2015, 46, 82-92. | 1.7 | 85 |
| 40 | Maternal racial origin and adverse pregnancy outcome: a cohort study. Ultrasound in Obstetrics and Gynecology, 2013, 41, 278-285. | 1.7 | 83 |
| 41 | Prediction of miscarriage and stillbirth at 11â€“13 weeks and the contribution of chorionic villus sampling. Prenatal Diagnosis, 2011, 31, 38-45. | 2.3 | 81 |
| 42 | Prospective firstâ€trimester screening for trisomies by cellâ€free DNA testing of maternal blood in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2016, 47, 705-711. | 1.7 | 80 |
| 43 | Maternal Serum Visfatin at 11â€“13 Weeks of Gestation in Gestational Diabetes Mellitus. Clinical Chemistry, 2011, 57, 609-613. | 3.2 | 78 |
| 44 | Maternal hemodynamics at 11â€“13 weeks' gestation and risk of preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2012, 40, 28-34. | 1.7 | 76 |
| 45 | Placental Volume at 11â€“13 Weeksâ€™ Gestation in the Prediction of Birth Weight Percentile. Fetal Diagnosis and Therapy, 2011, 30, 23-28. | 1.4 | 72 |
| 46 | Firstâ€trimester screening for trisomies by cfDNA testing of maternal blood in singleton and twin pregnancies: factors affecting test failure. Ultrasound in Obstetrics and Gynecology, 2019, 53, 804-809. | 1.7 | 66 |
| 47 | Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35â€“37 weeksâ€™ gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 486.e1-486.e11. | 1.3 | 63 |
| 48 | Maternal plasma inhibin A at 11â€“13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis, 2009, 29, 753-760. | 2.3 | 61 |
| 49 | Umbilical and fetal middle cerebral artery Doppler at 30â€“34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2015, 45, 409-420. | 1.7 | 61 |
| 50 | Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation, 2021, 144, 670-679. | 1.6 | 61 |
| 51 | Prediction of smallâ€forâ€gestationalâ€age neonates: screening by fetal biometry at 30â€“34 weeks. Ultrasound in Obstetrics and Gynecology, 2015, 45, 551-558. | 1.7 | 60 |
| 52 | Value of routine ultrasound examination at 35â€“37 weeks' gestation in diagnosis of fetal abnormalities. Ultrasound in Obstetrics and Gynecology, 2020, 55, 75-80. | 1.7 | 59 |
| 53 | First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. Fetal Diagnosis and Therapy, 2015, 38, 14-21. | 1.4 | 58 |
| 54 | Synergy of Total PLAC4 RNA Concentration and Measurement of the RNA Single-Nucleotide Polymorphism Allelic Ratio for the Noninvasive Prenatal Detection of Trisomy 21. Clinical Chemistry, 2010, 56, 73-81. | 3.2 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Fetal RHD genotype detection from circulating cellâ€free fetal DNA in maternal plasma in nonâ€sensitized RhD negative women. Prenatal Diagnosis, 2011, 31, 802-808. | 2.3 | 57 |
| 56 | Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 194-202. | 1.7 | 57 |
| 57 | Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 203-209. | 1.7 | 55 |
| 58 | Diagnosis of major heart defects by routine firstâ€trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus. Ultrasound in Obstetrics and Gynecology, 2020, 55, 637-644. | 1.7 | 55 |
| 59 | Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2012, 31, 87-93. | 1.4 | 54 |
| 60 | Association between firstâ€trimester maternal serum pregnancyâ€associated plasma proteinâ€A and obstetric complications. Prenatal Diagnosis, 2013, 33, 839-847. | 2.3 | 54 |
| 61 | Asymmetric dimethylarginine, arginine and homoarginine at 11â€“13 weeksâ€™ gestation and preeclampsia: a caseâ€control study. Journal of Human Hypertension, 2013, 27, 38-43. | 2.2 | 54 |
| 62 | Endoscopic Placental Laser Coagulation in Monochorionic Diamniotic Twins with Type II Selective Fetal Growth Restriction. Fetal Diagnosis and Therapy, 2015, 38, 86-93. | 1.4 | 54 |
| 63 | ASPRE trial: incidence of preterm preâ€eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. Ultrasound in Obstetrics and Gynecology, 2018, 51, 738-742. | 1.7 | 54 |
| 64 | Fetal RHD Genotyping in Maternal Plasma at 11â€“13 Weeks of Gestation. Fetal Diagnosis and Therapy, 2011, 29, 301-306. | 1.4 | 53 |
| 65 | Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. Ultrasound in Obstetrics and Gynecology, 2015, 46, 437-445. | 1.7 | 53 |
| 66 | Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal Abnormalities. Fetal Diagnosis and Therapy, 2014, 35, 174-184. | 1.4 | 51 |
| 67 | Validation of metabolomic models for prediction of early-onset preeclampsia. American Journal of Obstetrics and Gynecology, 2015, 213, 530.e1-530.e10. | 1.3 | 51 |
| 68 | Routine assessment of cerebroplacental ratio at 35â€“37ÂweeksÂâ€™ gestation in the prediction of adverseÂperinatal outcome. American Journal of Obstetrics and Gynecology, 2019, 221, 65.e1-65.e18. | 1.3 | 50 |
| 69 | Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. American Journal of Obstetrics and Gynecology, 2021, 224, 86.e1-86.e19. | 1.3 | 50 |
| 70 | Is high fetal nuchal translucency associated with submicroscopic chromosomal abnormalities on array <scp>CGH</scp>?. Ultrasound in Obstetrics and Gynecology, 2014, 43, 620-624. | 1.7 | 49 |
| 71 | Maternal plasma soluble fmsâ€like tyrosine kinaseâ€1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenatal Diagnosis, 2010, 30, 191-197. | 2.3 | 48 |
| 72 | Criteria for Screening and Diagnosis of Gestational Diabetes Mellitus in the First Trimester of Pregnancy. Fetal Diagnosis and Therapy, 2011, 30, 108-115. | 1.4 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Maternal and Neonatal Outcomes of Successful Kielland's Rotational Forceps Delivery. Obstetrics and Gynecology, 2013, 121, 1032-1039. | 2.4 | 40 |
| 74 | Maternal serum vitamin D levels at 11â€“13 weeks of gestation in preeclampsia. Journal of Human Hypertension, 2013, 27, 115-118. | 2.2 | 40 |
| 75 | Prediction of stillbirth from maternal demographic and pregnancy characteristics. Ultrasound in Obstetrics and Gynecology, 2016, 48, 607-612. | 1.7 | 39 |
| 76 | Prediction of largeâ€forâ€gestationalâ€age neonate by routine thirdâ€trimester ultrasound. Ultrasound in Obstetrics and Gynecology, 2019, 54, 326-333. | 1.7 | 39 |
| 77 | Routine ultrasound at 32 vs 36 weeks' gestation: prediction of smallâ€forâ€gestationalâ€age neonates. Ultrasound in Obstetrics and Gynecology, 2019, 53, 761-768. | 1.7 | 39 |
| 78 | Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis, 2009, 29, 934-938. | 2.3 | 38 |
| 79 | Fetal sex determination using circulating cellâ€free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation. Prenatal Diagnosis, 2010, 30, 918-923. | 2.3 | 38 |
| 80 | Maternal Thyroid Function at 11â€“13 Weeks of Gestation. Fetal Diagnosis and Therapy, 2010, 27, 156-163. | 1.4 | 38 |
| 81 | Association of placental volume measured by MRI and birth weight percentile. Journal of Magnetic Resonance Imaging, 2011, 34, 1125-1130. | 3.4 | 38 |
| 82 | Maternal and neonatal complications of fetal macrosomia: cohort study. Ultrasound in Obstetrics and Gynecology, 2019, 54, 319-325. | 1.7 | 38 |
| 83 | Maternal Serum Activin A at 11–13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Fetal Diagnosis and Therapy, 2009, 25, 320-327. | 1.4 | 35 |
| 84 | Metabolomic determination of pathogenesis of late-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 658-664. | 1.5 | 35 |
| 85 | Procedureâ€related risk of miscarriage following chorionic villus sampling and amniocentesis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 452-457. | 1.7 | 35 |
| 86 | Maternal serum adiponectin at 11 to 13 weeks of gestation in the prediction of macrosomia. Prenatal Diagnosis, 2011, 31, 479-483. | 2.3 | 34 |
| 87 | Prediction of stillbirth from biochemical and biophysical markers at 11â€“13 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 613-617. | 1.7 | 34 |
| 88 | Epigenetic-Genetic Chromosome Dosage Approach for Fetal Trisomy 21 Detection Using an Autosomal Genetic Reference Marker. PLoS ONE, 2010, 5, e15244. | 2.5 | 33 |
| 89 | Contribution of Method of Conception on Pregnancy Outcome after the 11â€“13 Weeks Scan. Fetal Diagnosis and Therapy, 2011, 30, 9-22. | 1.4 | 32 |
| 90 | Prevention of stillbirth: impact of twoâ€stage screening for vasa previa. Ultrasound in Obstetrics and Gynecology, 2020, 55, 605-612. | 1.7 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Assisted conception and placental perfusion assessed by uterine artery Doppler at 11-13 weeks' gestation. Human Reproduction, 2011, 26, 1659-1664. | 0.9 | 31 |
| 92 | Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks' Gestation. Fetal Diagnosis and Therapy, 2013, 34, 241-247. | 1.4 | 31 |
| 93 | Association of chronic hypertension with birth of smallâ€forâ€gestationalâ€age neonate. Ultrasound in Obstetrics and Gynecology, 2017, 50, 361-366. | 1.7 | 31 |
| 94 | Maternal serum 25-hydroxyvitamin D levels at 11+0-13+6â€ƒweeks in pregnant women with diabetes mellitus and in those with macrosomic neonates. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 951-955. | 2.3 | 30 |
| 95 | First-trimester maternal serum vitamin D and mode of delivery. British Journal of Nutrition, 2012, 108, 1972-1975. | 2.3 | 30 |
| 96 | Prediction of adverse perinatal outcome by cerebroplacental ratio in women undergoing induction of labor. Ultrasound in Obstetrics and Gynecology, 2019, 53, 473-480. | 1.7 | 30 |
| 97 | Maternal Serum Î±-Fetoprotein at 11â€“13 Weeksâ€™ Gestation in Spontaneous Early Preterm Delivery. Fetal Diagnosis and Therapy, 2011, 30, 88-93. | 1.4 | 29 |
| 98 | Prediction of smallâ€forâ€gestationalâ€age neonates at 35â€“37â€‰weeks' gestation: contribution of maternal factors and growth velocity between 20 and 36â€‰weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 488-495. | 1.7 | 29 |
| 99 | Perinatal outcome of pregnancies with prenatal diagnosis of vasa previa: systematic review and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2021, 57, 710-719. | 1.7 | 29 |
| 100 | Fetal middle cerebral artery and umbilical artery pulsatility index: effects of maternal characteristics and medical history. Ultrasound in Obstetrics and Gynecology, 2015, 45, 402-408. | 1.7 | 28 |
| 101 | Biomarkers of impaired placentation at 35â€“37â€‰weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2019, 54, 79-86. | 1.7 | 28 |
| 102 | Routine firstâ€trimester screening for fetal trisomies in twin pregnancy: cellâ€free DNA test contingent on results from combined test. Ultrasound in Obstetrics and Gynecology, 2019, 53, 208-213. | 1.7 | 28 |
| 103 | Cellâ€free <scp>DNA</scp> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10â€“14â€‰weeks and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2021, 58, 178-189. | 1.7 | 28 |
| 104 | First trimester urinary placental growth factor and development of preâ€eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 643-647. | 2.3 | 27 |
| 105 | Association between reduced fetal movements at term and abnormal uterine artery Doppler indices. Ultrasound in Obstetrics and Gynecology, 2014, 43, 548-552. | 1.7 | 27 |
| 106 | Proposed clinical management of pregnancies after combined screening for preâ€eclampsia at 35â€“37 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 50, 383-387. | 1.7 | 27 |
| 107 | Screening for preâ€eclampsia using sFltâ€1/PlGF ratio cutâ€off of 38 at 30â€“37 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 73-77. | 1.7 | 27 |
| 108 | Twoâ€stage approach for prediction of smallâ€forâ€gestationalâ€age neonate and adverse perinatal outcome by routine ultrasound examination at 35â€“37â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 484-491. | 1.7 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review of the literature. Minerva Obstetrics and Gynecology, 2018, 70, 215-219. | 1.0 | 27 |
| 110 | Maternal serum insulinâ€like growth factorâ€I at 11â€“13 weeks in preeclampsia. Prenatal Diagnosis, 2010, 30, 1026-1031. | 2.3 | 26 |
| 111 | Systematic Identification of Placental Epigenetic Signatures for the Noninvasive Prenatal Detection of Edwards Syndrome. PLoS ONE, 2010, 5, e15069. | 2.5 | 25 |
| 112 | Maternal Serum Vitamin D at 11â€“13 Weeks in Pregnancies Delivering Small for Gestational Age Neonates. Fetal Diagnosis and Therapy, 2012, 31, 103-108. | 1.4 | 25 |
| 113 | Maternal Hemodynamics at 11Â–13 Weeks of Gestation in Pregnancies Delivering Small for Gestational Age Neonates. Fetal Diagnosis and Therapy, 2012, 32, 231-238. | 1.4 | 25 |
| 114 | Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 30-34 weeks. Ultrasound in Obstetrics and Gynecology, 2015, 45, 707-714. | 1.7 | 25 |
| 115 | Social Brain Functional Maturation in Newborn Infants With and Without a Family History of Autism Spectrum Disorder. JAMA Network Open, 2019, 2, e191868. | 5.9 | 25 |
| 116 | Maternal Serum Adiponectin at 11â€“13 Weeks of Gestation in Preeclampsia. Fetal Diagnosis and Therapy, 2011, 29, 208-215. | 1.4 | 24 |
| 117 | Uterine artery pulsatility index at 30â€“34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 308-315. | 1.7 | 24 |
| 118 | Fetal major cardiac defects and placental dysfunction at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 51, 194-198. | 1.7 | 24 |
| 119 | Diagnosis of fetal defects in twin pregnancies at routine 11â€“13â€week ultrasound examination. Ultrasound in Obstetrics and Gynecology, 2020, 55, 474-481. | 1.7 | 24 |
| 120 | Prediction of stillbirth from placental growth factor at 11â€“13 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 618-623. | 1.7 | 22 |
| 121 | Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19â€“24 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 624-630. | 1.7 | 21 |
| 122 | Impaired placentation in women with chronic hypertension who develop preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2017, 50, 496-500. | 1.7 | 21 |
| 123 | Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 194-200. | 1.7 | 21 |
| 124 | Maternal Hemodynamics at 11â€“13 Weeksâ€™ Gestation in Gestational Diabetes Mellitus. Fetal Diagnosis and Therapy, 2012, 31, 216-220. | 1.4 | 20 |
| 125 | Prenatal prediction of need for ventriculoperitoneal shunt in open spina bifida. Ultrasound in Obstetrics and Gynecology, 2014, 43, 159-164. | 1.7 | 20 |
| 126 | Maternal Hemodynamics in Normal Pregnancies at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2012, 32, 179-185. | 1.4 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF. Ultrasound in Obstetrics and Gynecology, 2017, 49, 201-208. | 1.7 | 19 |
| 128 | Value of routine ultrasound examination at 35â€“37â€‰weeks' gestation in diagnosis of nonâ€cephalic presentation. Ultrasound in Obstetrics and Gynecology, 2020, 55, 248-256. | 1.7 | 19 |
| 129 | Impact of prospective measurement of outflow tracts inÂprediction of coarctation of the aorta. Ultrasound in Obstetrics and Gynecology, 2020, 56, 850-856. | 1.7 | 19 |
| 130 | Comparison of closure of subcutaneous tissue versus non-closure in relation to wound disruption after abdominal hysterectomy in obese patients. Journal of Postgraduate Medicine, 2000, 46, 26-8. | 0.4 | 19 |
| 131 | Prediction of smallâ€forâ€gestationalâ€age neonates at 35â€“37 weeks' gestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 630-637. | 1.7 | 18 |
| 132 | Midbrain and Falx in Fetuses with Absent Corpus Callosum at 11â€“13 Weeks. Fetal Diagnosis and Therapy, 2013, 33, 41-46. | 1.4 | 17 |
| 133 | Maternal and pregnancy characteristics affect plasma fibrin monomer complexes and D-dimer reference ranges for venous thromboembolism in pregnancy. American Journal of Obstetrics and Gynecology, 2016, 215, 466.e1-466.e8. | 1.3 | 17 |
| 134 | Reference Ranges for the Size of the Fetal Cardiac Outflow Tracts From 13 to 36 Weeks Gestation. Circulation: Cardiovascular Imaging, 2018, 11, e007575. | 2.6 | 17 |
| 135 | Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. American Journal of Obstetrics and Gynecology, 2020, 223, 246.e1-246.e10. | 1.3 | 17 |
| 136 | Maternal serum visfatin at 11â€“13 weeksâ€™ gestation in preeclampsia. Journal of Human Hypertension, 2013, 27, 261-264. | 2.2 | 16 |
| 137 | Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age. Fetal Diagnosis and Therapy, 2018, 43, 250-265. | 1.4 | 16 |
| 138 | Maternal Serum Alpha-Fetoprotein in Normal Pregnancy at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2011, 30, 274-279. | 1.4 | 15 |
| 139 | Maternal serum placental growth hormone at 11â€“13 weeksâ€™ gestation in pregnancies delivering small for gestational age neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1796-1799. | 1.5 | 15 |
| 140 | Prediction of stillbirth from placental growth factor at 19â€“24 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 631-635. | 1.7 | 15 |
| 141 | Evaluation of the RCOG guideline for the prediction of neonates that are small for gestational age and comparison with the competing risks model. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 2110-2115. | 2.3 | 15 |
| 142 | <scp>STATIN</scp> trial: predictive performance of competingâ€risks model in screening for preâ€eclampsia at 35â€“37â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 69-75. | 1.7 | 15 |
| 143 | A new direction for prenatal chromosome microarray testing: software-targeting for detection of clinically significant chromosome imbalance without equivocal findings. PeerJ, 2014, 2, e354. | 2.0 | 15 |
| 144 | Maternal Serum Progesterone-Induced Blocking Factor at 11â€“13 Weeksâ€™ Gestation in Spontaneous Early Preterm Delivery. Fetal Diagnosis and Therapy, 2011, 29, 197-200. | 1.4 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11â€“13 weeks in preeclampsia. Journal of Human Hypertension, 2012, 26, 253-258. | 2.2 | 13 |
| 146 | Impaired placental perfusion and major fetal cardiac defects. Ultrasound in Obstetrics and Gynecology, 2019, 53, 68-72. | 1.7 | 13 |
| 147 | Comparison of different methods of measuring angle of progression in prediction of labor outcome. Ultrasound in Obstetrics and Gynecology, 2020, 55, 391-400. | 1.7 | 13 |
| 148 | Development and validation of model for prediction of placental dysfunctionâ€related stillbirth from maternal factors, fetal weight and uterine artery Doppler at midâ€gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 61-68. | 1.7 | 13 |
| 149 | Chorionic Villus Sampling at 11 to 13 Weeks of Gestation and Hypertensive Disorders in Pregnancy. Obstetrics and Gynecology, 2010, 116, 374-380. | 2.4 | 12 |
| 150 | Maternal serum insulinâ€like growth factorâ€binding proteinâ€1 (IGFBPâ€1) at 11â€“13 weeks in preâ€eclampsia. Prenatal Diagnosis, 2011, 31, 196-201. | 2.3 | 12 |
| 151 | Normal Range of Maternal Serum Vitamin D at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2011, 30, 94-99. | 1.4 | 12 |
| 152 | Secondâ€trimester contingent screening for smallâ€forâ€gestationalâ€age neonate. Ultrasound in Obstetrics and Gynecology, 2022, 59, 177-184. | 1.7 | 12 |
| 153 | Maternal Serum Human Placental Growth Hormone (hPGH) at 11 to 13 Weeks of Gestation in Preeclampsia. Hypertension in Pregnancy, 2011, 30, 74-82. | 1.1 | 11 |
| 154 | Predictive performance for placental dysfunction related stillbirth of the competing risks model for smallâ€forâ€gestationalâ€age fetuses. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1530-1537. | 2.3 | 11 |
| 155 | Rupture of left horn of bicornuate uterus at twenty weeks of gestation. Journal of Postgraduate Medicine, 2000, 46, 39-40. | 0.4 | 11 |
| 156 | Maternal Plasma P-selectin at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Hypertension in Pregnancy, 2011, 30, 311-321. | 1.1 | 10 |
| 157 | Maternal serum angiopoietinâ€2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis, 2009, 29, 847-851. | 2.3 | 9 |
| 158 | Timing of birth in multiple pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 319-326. | 2.8 | 9 |
| 159 | Fetal intraâ€abdominal bowel dilation in prediction ofÂcomplex gastroschisis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 376-380. | 1.7 | 9 |
| 160 | Fetal loss after chorionic villus sampling in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2021, 58, 48-55. | 1.7 | 9 |
| 161 | Reference Ranges for Pulsed-Wave Doppler of the Fetal Cardiac Inflow and Outflow Tracts from 13 to 36ÂWeeksâ€™ Gestation. Journal of the American Society of Echocardiography, 2021, 34, 1007-1016.e10. | 2.8 | 9 |
| 162 | Risk of fetal loss after chorionic villus sampling in twin pregnancy derived from propensity score matching analysis. Ultrasound in Obstetrics and Gynecology, 2022, 59, 162-168. | 1.7 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11â€“13 Weeks?. Fetal Diagnosis and Therapy, 2011, 30, 53-59. | 1.4 | 8 |
| 164 | Pregnancy Loss Following Amniocentesis or CVS Samplingâ€”Time for a Reassessment of Risk. Journal of Clinical Medicine, 2014, 3, 741-746. | 2.4 | 8 |
| 165 | Endoscopic Placental Laser Coagulation in Dichorionic and Monochorionic Triplet Pregnancies. Fetal Diagnosis and Therapy, 2016, 40, 174-180. | 1.4 | 8 |
| 166 | Maternal race and preâ€eclampsia: Cohort study and systematic review with metaâ€analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 2082-2093. | 2.3 | 8 |
| 167 | Maternal Serum Placental Protein 13 at Eleven to Thirteen Weeks in Chromosomally Abnormal Pregnancies. Fetal Diagnosis and Therapy, 2010, 27, 72-77. | 1.4 | 7 |
| 168 | Multiplex ligation-dependent probe amplification (MLPA): a reliable alternative for fetal chromosome analysis?. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1383-1386. | 1.5 | 7 |
| 169 | Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. Obstetric Medicine, 2017, 10, 170-173. | 1.1 | 7 |
| 170 | Maternal Plasma Plasminogen Activator Inhibitor-2 at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Hypertension in Pregnancy, 2011, 30, 194-202. | 1.1 | 6 |
| 171 | Maternal Race and Stillbirth: Cohort Study and Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3452. | 2.4 | 6 |
| 172 | Effect of Chorionic Villus Sampling on Uterine Artery Doppler. Fetal Diagnosis and Therapy, 2010, 28, 9-13. | 1.4 | 5 |
| 173 | Maternal Serum Adiponectin at 11â€“13 Weeks of Gestation in Pregnancies Delivering Small for Gestation Neonates. Fetal Diagnosis and Therapy, 2011, 29, 274-279. | 1.4 | 5 |
| 174 | Biparietal diameter at 11 to 13â€‰weeks' gestation in fetuses with holoprosencephaly. Prenatal Diagnosis, 2014, 34, 134-138. | 2.3 | 5 |
| 175 | Kiellandâ€™s rotational forceps delivery: A comparison of maternal and neonatal outcomes with rotational ventouse or second stage caesarean section deliveries. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 254, 175-180. | 1.1 | 5 |
| 176 | Fetal fraction of cell free DNA in screening for hypertensive disorders at 11â€“13 weeks. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 5363-5368. | 1.5 | 5 |
| 177 | Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2020, 7, 1-156. | 0.7 | 5 |
| 178 | Procedure-related pregnancy loss following invasive prenatal sampling: time for a new approach to risk assessment and counseling. Expert Review of Obstetrics and Gynecology, 2013, 8, 135-142. | 0.4 | 4 |
| 179 | Re: Risk of fetal loss associated with invasive testing following combined firstâ€trimester screening for Down syndrome: a national cohort of 147â€‰987 singleton pregnancies. C. B. Wulff, T. A. Gerds, L. Rode, C. K. Ekelund, O. B. Petersen, A. Tabor and the Danish Fetal Medicine Study Group. Ultrasound Obstet Gynecol 2016; 47: 38â€“44. Ultrasound in Obstetrics and Gynecology, 2016, 47, 14-14. | 1.7 | 4 |
| 180 | Maternal and neonatal outcomes following Kielland's rotational forceps delivery. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, Fa9-Fa9. | 2.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | First trimester maternal uterine artery Doppler examination in HIV-positive women. HIV Medicine, 2011, 12, 632-636. | 2.2 | 3 |
| 182 | Adrenal gland length in euploid and trisomy 18 fetuses at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 773-777. | 2.3 | 3 |
| 183 | P14â€…Significance and associations of aberrant right subclavian artery in the fetal cardiology setting. Heart, 2016, 102, A7.2-A8. | 2.9 | 3 |
| 184 | Prediction of adverse perinatal outcome by serum placental growth factor and soluble fmsâ€like tyrosine kinaseâ€1 in women undergoing induction of labor. Ultrasound in Obstetrics and Gynecology, 2019, 54, 604-608. | 1.7 | 3 |
| 185 | OS084. Maternal haemodynamics at 11â€“13 weeks of gestation and adverse pregnancy outcomes. Pregnancy Hypertension, 2012, 2, 223-224. | 1.4 | 2 |
| 186 | Reply. Ultrasound in Obstetrics and Gynecology, 2015, 45, 755-757. | 1.7 | 2 |
| 187 | Risk of Miscarriage Following Amniocentesis or Chorionic Villus Sampling: Systematic Review of Literature and Updated Meta-analysis. Obstetrical and Gynecological Survey, 2020, 75, 152-154. | 0.4 | 2 |
| 188 | Kiellandâ€™s rotational forceps delivery: comparison of maternal and neonatal outcomes with pregnancies delivering by non-rotational forceps. Journal of Obstetrics and Gynaecology, 2022, 42, 379-384. | 0.9 | 2 |
| 189 | Chronic Hypertension and Adverse Pregnancy Outcome: A Cohort Study. Obstetrical and Gynecological Survey, 2018, 73, 7-8. | 0.4 | 1 |
| 190 | Reply. American Journal of Obstetrics and Gynecology, 2019, 221, 659. | 1.3 | 1 |
| 191 | Reply. Ultrasound in Obstetrics and Gynecology, 2015, 46, 253-254. | 1.7 | 0 |
| 192 | Metabolomic Analysis for First Trimester Down Syndrome Prediction. Obstetric Anesthesia Digest, 2015, 35, 35-36. | 0.1 | 0 |
| 193 | Reply. Ultrasound in Obstetrics and Gynecology, 2016, 47, 789-789. | 1.7 | 0 |
| 194 | Reply. Ultrasound in Obstetrics and Gynecology, 2017, 49, 666-667. | 1.7 | 0 |
| 195 | Reply. Ultrasound in Obstetrics and Gynecology, 2020, 56, 953-954. | 1.7 | 0 |
| 196 | Maternal and Neonatal Complications of Fetal Macrosomia: Systematic Review and Meta-analysis. Obstetrical and Gynecological Survey, 2020, 75, 148-149. | 0.4 | 0 |
| 197 | Multiplex ligation-dependent probe amplification: a reliable and cost efficient 'single-test' alternative for fetal chromosome analysis?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, Fa17-Fa18. | 2.8 | 0 |
| 198 | Estimated fetal weight at midâ€gestation in prediction of preâ€eclampsia in singleton pregnancies. Ultrasound in Obstetrics and Gynecology, 2021, , . | 1.7 | 0 |